The DOCK2 Knockout HeLa Polyclonal Cells product provides a ready-to-use CRISPR/Cas9-edited polyclonal cell population derived from the HeLa human cervical adenocarcinoma cell line. This polyclonal knockout pool is generated via CRISPR/Cas9-mediated disruption of the DOCK2 locus, creating a heterogeneous loss-of-function model suitable for studying DOCK2-dependent signaling and cellular processes. The polyclonal nature of the edited population preserves the genetic diversity typically encountered in pooled screening approaches and functional assays, enabling robust assessment of gene function in an epithelial cancer background.
HeLa cells are an established adherent, epithelial-like human cell line originally isolated from cervical adenocarcinoma tissue. They exhibit rapid proliferation, stable karyotype, and extensive historical characterization in cancer biology, virology, and signal transduction research. Their robust growth characteristics and well-documented responsiveness to chemokine and growth factor stimulation make HeLa cells particularly suited for investigating cytoskeletal rearrangements and cell migration, endpoints critically linked to DOCK2 activity.
DOCK2 encodes a guanine nucleotide exchange factor (GEF) that specifically activates Rac small GTPases by catalyzing GDP-to-GTP exchange. Upon stimulation through chemokine receptors such as CXCR4 and CCR7, or antigen receptors including TCR and BCR, DOCK2 forms a ternary complex with the adaptor proteins ELMO1 and CRK. This complex facilitates the localized activation of Rac1 and Rac2, which in turn triggers downstream effectors including the WAVE regulatory complex and the Arp2/3 complex, leading to branched actin polymerization. Rac also activates PAK1, which regulates cofilin-dependent actin remodeling, promoting directional cell migration and immune synapse formation. Thus, DOCK2 functions as a critical node coupling extracellular guidance cues to cytoskeletal dynamics.
In the HeLa epithelial background, DOCK2 knockout disrupts Rac-mediated actin remodeling and impairs chemotactic migration, providing a valuable tool for dissecting the molecular underpinnings of cancer cell invasion and metastasis. Although DOCK2 is best characterized in hematopoietic cells, its expression in HeLa cells enables interrogation of non-immune roles for this GEF in epithelial migration, proliferation, and potentially tumor progression. This polyclonal knockout model allows researchers to examine the consequences of DOCK2 loss in a heterogeneous cell population, mimicking the clonal diversity often seen in tumor evolution and offering insights into variable cellular responses to extracellular stimuli.
Typical experimental applications include chemotaxis and transwell migration assays to quantify directional movement, immunofluorescence microscopy of actin cytoskeleton and focal adhesions to visualize structural changes, and GTPase activation assays (e.g., PAK-1 phospho-detection or Rac-GTP pull-down) for biochemical readouts of pathway activity. The polyclonal DOCK2 knockout cells are also suitable for co-immunoprecipitation studies to assess DOCK2 interactions, RT-qPCR-based cytokine profiling, and flow cytometric analysis of surface markers. For detailed product information, validation data, and customized cell-based solutions, please contact Ascent Research.
